{"id":491562,"date":"2020-06-22T18:30:01","date_gmt":"2020-06-22T18:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=491562"},"modified":"2020-06-22T18:30:01","modified_gmt":"2020-06-22T18:30:01","slug":"protein-engineering-market-worth-39-billion-by-2024-key-players-thermo-fisher-scientific-us-danaher-corporation-us","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/protein-engineering-market-worth-39-billion-by-2024-key-players-thermo-fisher-scientific-us-danaher-corporation-us_491562.html","title":{"rendered":"Protein Engineering Market Worth $3.9 Billion by 2024 | Key Players Thermo Fisher Scientific (US), Danaher Corporation (US)"},"content":{"rendered":"
\"Protein<\/a><\/p>\n
\n
Biopharmaceutical companies were the largest end users of protein engineering products and services in 2019<\/div>\n<\/div>\n<\/div>\n
Protein Engineering Market Report Provides Crucial Industry Insights That Will Help Your Business Grow. Know The Key Industry Trends.<\/div>\n

According to the new market research report “<\/strong>Protein Engineering Market by Technology (Rational Design, Irrational Design), Product & Service (Instrument, Consumables), Protein Type (Monoclonal Antibodies, Insulin), End User (Academics Institutes, Biopharmaceuticals, CROs) – Global Forecast to 2024″<\/strong>, published by MarketsandMarkets™, the Protein Engineering Market is estimated to grow from USD 2.2 billion<\/span> in 2019 to USD 3.9 billion<\/span> by 2024, at a CAGR of 12.4% during the forecast period.<\/p>\n

Download PDF Brochure:
<\/strong>https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=898<\/a> <\/p>\n

Factors such as the increasing investments in synthetic biology and the growing focus on protein-based drug development by pharmaceutical and biotechnology companies are expected to drive the growth of this market in the coming years. <\/p>\n

\"protein-antibody-engineering-market1\"<\/p>\n

Instruments segment accounted for the largest share of the Protein Engineering Market, by product & service, in 2019<\/p>\n

<\/strong>Based on product & service, the market is segmented into instruments, consumables, and software & services. Instruments accounted for the largest share of this market in 2019 owing to the technological advancements in mass spectrometry and X-ray crystallography and their ability to integrate with other technologies.<\/p>\n

Monoclonal antibodies segment accounted for the largest share of the Protein Engineering Market, by protein type, in 2019<\/p>\n

<\/strong>Based on protein type, the market is segmented into monoclonal antibodies, insulin, erythropoietin, interferons, vaccines, colony-stimulating factors, growth hormones, coagulation factors, and other proteins. Monoclonal antibodies accounted for the largest share of the market in 2019, majorly due to the high and growing demand for monoclonal antibodies for the treatment of cancer, neurological diseases, and infectious diseases.<\/p>\n

Browse in-depth TOC on<\/em> “<\/strong>Protein Engineering Market<\/a><\/strong>“<\/p>\n

<\/strong>132 – Tables
<\/strong>32 – Figures
<\/strong>146 – Pages<\/p>\n

<\/strong>Rational protein design was the largest technology segment in the Protein Engineering Market in 2019<\/p>\n

<\/strong>Based on technology, the market is segmented into rational and irrational protein design. The rational protein design segment accounted for the largest share of the market, majorly due to the increasing use and continuous upgrades of bioinformatics platforms and software for protein analysis.<\/p>\n

Biopharmaceutical companies were the largest end users of protein engineering products and services in 2019<\/p>\n

<\/strong>Based on end user, the Protein Engineering Market is segmented into biopharmaceutical companies, contract research organizations, and academic research institutes. Biopharmaceutical companies use protein engineering products extensively in their drug discovery and development activities as these products help in designing models to develop a broad range of protein-based drugs. As a result, biopharmaceutical companies were the largest end users in this market in 2019.<\/p>\n

Request Sample Pages:
https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=898<\/a> <\/strong><\/p>\n

North America<\/span> was the largest regional market for protein engineering products and services in 2019<\/p>\n

<\/strong>In 2019, North America<\/span> accounted for the largest share of the global market, followed by Europe<\/span>. The large share of the North American market is attributed to the presence of well-established CROs, rising R&D expenditure, and the availability of the latest techniques and instruments for drug discovery research in the region. Also, the rising adoption of biologic drugs such as monoclonal antibodies, erythropoietin, and interferons for the treatment of chronic diseases is a major factor driving the growth of the North American market.<\/p>\n

The major companies operating in the global Protein Engineering Market include Thermo Fisher Scientific (US), Danaher Corporation (US), Agilent Technologies (US), and Bio-Rad Laboratories (US).<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> MarketsandMarkets<\/a>
Contact Person:<\/strong> Mr. Aashish Mehra
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 18886006441
Address:<\/strong>630 Dundee Road Suite 430
City:<\/strong> Northbrook
State:<\/strong> IL 60062
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.marketsandmarkets.com\/Market-Reports\/protein-antibody-engineering-market-898.html<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Biopharmaceutical companies were the largest end users of protein engineering products and services in 2019 Protein Engineering Market Report Provides Crucial Industry Insights That Will Help Your Business Grow. Know The Key Industry Trends. According to the new market research … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,417,406],"tags":[],"class_list":["post-491562","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/491562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=491562"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/491562\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=491562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=491562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=491562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}